Status: Recruiting
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Participants needed: 13
Trial details
Phase: Phase 2Age: 2-25Biological sex: AllType: InterventionalSponsor: Children's Hospital of PhiladelphiaUpdated: Apr 15, 2026Locations: 4
Eligibility criteria
Age 2-25 years, inclusive [+13]
No prior systemic therapy for thyroid cancer, including RET inhibitors. Note: pr... [+7]